Kissei Braced for 65% Sales Fall for Urief on Generic Onslaught; Exec Admits Uphill Battle for Nesp Biosimilar

Kissei Pharmaceutical racked up record sales of 17.81 billion yen for its mainstay dysuria drug Urief (silodosin) in FY2019 through March, but is expected to suffer a hefty slide in the number in the current fiscal year as it braces...read more